Milestone Pharmaceuticals Q4 GAAP EPS $(0.32) Misses $(0.31) Estimate; Cash Balance Of $66M Expected To Provide Cash Runway Into 2026
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals (NASDAQ:MIST) reported a Q4 GAAP EPS of $(0.32), missing the $(0.31) estimate by 3.23%. The company's cash balance of $66M is expected to provide a cash runway into 2026, indicating a slight decrease in losses from the same period last year.
March 21, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Milestone Pharmaceuticals reported a Q4 GAAP EPS of $(0.32), missing estimates by 3.23%, with a cash balance indicating stability into 2026.
Missing the EPS estimate, even by a small margin, can lead to negative investor sentiment in the short term. However, the significant cash balance provides some stability, indicating the company's ability to sustain operations into 2026. This mixed news could lead to short-term volatility in the stock price, but the negative impact of missing EPS estimates is likely to dominate investor reactions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100